Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies
Running, not enrolling · Phase 1/Phase 2
Conditions studied: Advanced Solid Malignancies
In brief
The purpose of this study is to test the safety of an investigational drug called CFI-402411 alone and in combination with pembrolizumab and to study its effects in patients with advanced solid tumors who have progressed following previous therapies.
Key facts
- Study ID
- NCT04521413
- Run by
- Treadwell Therapeutics, Inc
- People needed
- 170
- Starts
- 2020-08-31
- Expected to finish
- 2025-12-01
- Last updated by the study team
- 2025-05-21
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of California San Diego — La Jolla, California, United States
- The Angeles Clinic — Los Angeles, California, United States
- Yale Cancer Center — New Haven, Connecticut, United States
- Florida Cancer Specialists — Sarasota, Florida, United States
- START - Mid-West — Grand Rapids, Michigan, United States
- SCRI - Nashville — Nashville, Tennessee, United States
- MD Anderson — Houston, Texas, United States
- START - San Antonio — San Antonio, Texas, United States
- Virginia Cancer Specialist — Fairfax, Virginia, United States
- Cross Cancer Institute — Edmonton, Alberta, Canada
- The Ottawa Hospital — Ottawa, Ontario, Canada
- Princess Margaret Cancer Centre — Toronto, Ontario, Canada
- Prince of Wales Hospital — Shatin, Hong Kong
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.